Japan / Eisai Targeting Global Leadership in Neurology & Oncology Niches
Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has become a leading global biopharma…
Top Stories
Sanofi / The "Tortoise" of the COVID-19 Vaccine Race?
Sanofi CEO Paul Hudson ignited a heated debate around vaccine nationalism earlier this year when he suggested that the US, having made the biggest initial investment in Sanofi’s COVID-19 vaccine…
Europe / Ethics in Artificial Intelligence: Better Prepare Now
With upcoming EU regulation poised to have a massive impact on ethical regulations around AI in Europe, Bayer Head…
South Africa / Aspen Inks Deal to Manufacture J&J’s COVID-19 Vaccine
South African firm Aspen has inked a deal with Johnson & Johnson for the technical transfer and proposed…
USA / New Pharma Report 2020
The inaugural edition of the US Healthcare and Life Sciences Review has collated comments and insights from…
Global / Ebola Vaccine Lessons for COVID-19 & The Future of Global Health
Epidemiologist John-Arne Røttingen has had a long and distinguished career in both academia and industry,…
Biotech / Top 7 IPOs in 2020
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you the seven…
In Conversation
Miguel Forte – CEO, Bone Therapeutics, Belgium
Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the Belgian healthcare system and what makes the country a perfect environment for Bone Therapeutics as a biotech company focusing on innovative cell and gene therapy. My goal is to shape the organization to deliver on…
Latest Reports
Focus on Switzerland
Moving the Needle on Gender Diversity in Swiss Pharma…
While Switzerland has Europe's second-highest proportion of women in the…
What Three Pharma Leaders Want to Share About Switzerland
PharmaBoardroom highlights three of the most enterprising and dynamic pharma…
Post-Brexit UK Joins Australia, Canada, Singapore &…
When the European Medicines Agency (EMA) relocated from London to Amsterdam…
Abdi Ibrahim Buys 28.5% Stake in Swiss OM; A Historic Moment…
When Abdi Ibrahim acquired a 28.5 percent stake in Swiss biotech OM Pharma in…
Read more: Switzerland >>
Focus on MEA
COVID-19 / Lessons from MSD’s Ebola Vaccine Development:…
While outbreaks of the devastating Ebola virus have – thankfully – generally…
Top 10 Pharma Companies in Saudi Arabia
The top 10 pharma companies in Saudi Arabia ranked by sales value in USD…
Malaria Prevention Cannot be Allowed to Stall During the…
As COVID-19 threatens to derail more than a decade’s worth of hard-won gains…
Middle East & Africa Pharma News Roundup September 2020
A roundup of the latest news from pharma in the Middle East and Africa including…
Read more: MEA >>
Focus on Vaccines
PhRMA CEO on ‘Tireless’ Industry COVID-19 Response…
Stephen J. Ubl, president and CEO of PhRMA, outlines the unprecedented…
Ebola Vaccine Lessons for COVID-19 & The Future of…
Epidemiologist John-Arne Røttingen has had a long and distinguished career in…
6 Key Takeaways from GSK Vaccines Head Roger Connor at FT…
During the FT Global Pharmaceutical and Biotechnology Conference last week, GSK…
South Africa’s Aspen Inks Deal to Manufacture…
South African firm Aspen has inked a deal with Johnson & Johnson for the…
Read more: Vaccines >>
Focus on USA
Is the USA’s Innovation Leadership Position At-Risk?
David H. Crean, managing director for Objective Capital Partners, provides…
Aducanumab edges closer to Potential Approval: Next up, the…
In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding…
San Diego: What it Takes to be a Successful Life Science…
Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park highlights…
Takeda USA’s Ramona Sequeira Talks “Culture as…
After five years with Takeda heading up the Japan-headquartered pharma…
Read more: USA >>
Focus on Japan
Japan: The Latest Therapeutic Applications in Induced…
Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park looks at how…
Eisai Targeting Global Leadership in Neurology &…
Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has…
UK-Japan FTA: Banishing UK Pharma’s Brexit Blues
The signing of an agreement on the terms of a future trade relationship between…
How Chugai Became Japan’s Top Pharma Company
In 2020, Chugai Pharmaceutical Co. became Japan’s biggest drug company, driven…
Read more: Japan >>
Focus on China
China: 2020’s Biggest Biotech IPO in Profile
RemeGen, a low-profile Chinese biotech company based in Yantai city in the…
Edigene CEO on Gene Editing Biotech’s Ambitious Expansion…
Following a recent capital injection of USD 67 million, Chinese biotech EdiGene…
Top 7 Biotech IPOs in 2020
Following the recent news of Remegen's massive USD 515 million IPO in November…
China: Green Valley Alzheimer’s Trial; Samsung…
A roundup of the latest from Chinese pharma, including Green Valley's upcoming…
Read more: China >>
Focus on Europe
What Three Pharma Leaders Want to Share About Switzerland
PharmaBoardroom highlights three of the most enterprising and dynamic pharma…
France: Mid-2021 for Sanofi COVID-19 Vaccine; 1 Million…
A roundup of the latest stories from French pharma, including the progress of…
Ethics in Artificial Intelligence: Better Prepare Now
With upcoming EU regulation poised to have a massive impact on ethical…
Ebola Vaccine Lessons for COVID-19 & The Future of…
Epidemiologist John-Arne Røttingen has had a long and distinguished career in…